Live Feed

ARLINGTON, Va., July 28, 2026 /PRNewswire/ -- Second Quarter 2026Revenue increased to $24.6 billion primarily reflecting 171 commercial deliveriesGAAP loss per share of ($0.67) and core loss per share (non-GAAP)* of ($0.76)Operating cash flow of $1.4 billion and free cash flow (non-GAAP)* of $0.6 billionTotal company backlog grew to a record $715 billion, including over 6,200 commercial airplanesTable 1. Summary Financial ResultsSecond QuarterFirst Half(Dollars in Millions, except per share data)20262025Change20262025ChangeRevenues$24,560$22,7498 %$46,777$42,24511 %GAAPEarnings/(loss) from operations$156($176)NM$604$285112 %Operating margins0.6 %(0.8) %1.4 Pts1.3 %0.7 %0.6 PtsNet loss($428)(

Business unit leaders, Noelle O'Mara (Refrigerated and Frozen) and Jill Dexter (Grocery & Snacks), to report directly to CEO John Brase; Burke Raine to become chief growth officer, also reporting to Brase.Tom McGough, executive vice president and chief operating officer, to retire effective September 2026 after nearly two decades with Conagra BrandsCHICAGO, July 28, 2026 /PRNewswire/ -- Conagra Brands, Inc. (NYSE:CAG) today announced changes which will streamline the Company's structure. Noelle O'Mara, executive vice president and president of Refrigerated and Frozen and Jill Dexter, executive vice president and president of Grocery and Snacks, will report directly to president and chief exe

JUNO BEACH, Fla., July 28, 2026 /PRNewswire/ -- XPLR Infrastructure, LP (NYSE:XIFR) has posted its second-quarter 2026 financial results in a news release available on the company's website at www.XPLRInfrastructure.com/FinancialResults. Members of the company's senior management team will discuss the company's second-quarter 2026 financial results during an investor presentation to be webcast live, beginning at 9 a.m. ET today. The listen-only webcast will be available on XPLR Infrastructure's website by accessing the following link: www.XPLRInfrastructure.com/FinancialResults. A replay will be available for 90 days by accessi

NEWPORT BEACH, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our"), a diversified holding company executing a precision manufacturing growth strategy across the aerospace and defense supply chain, today announced that its wholly owned subsidiary, A&B Aerospace, Inc. ("A&B Aerospace"), has entered into a Long-Term Agreement (the "Agreement") with Precision Aerospace & Defense Group, Inc. ("PAD Group") to manufacture and supply precision-machined aerospace and defense components. The Agreement, effective July 23, 2026, establishes a two-year framework under which PAD Group and its subsidiaries may issue purchase orders to A&B Ae

– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 –– KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 28, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for dise

- Company’s third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease - WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IND application to initiate a Phase 1 clinical trial for DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). DYNE-302 leverages the same FORCE™ platform as Dyne’s first two clinical programs, zelec

PHINIA Inc. (NYSE:PHIN), a diversified, industrial supplier and global leader in the development of fuel systems, electrical systems and aftermarket solutions, announced today that it will participate in the Deutsche Bank Chicago Industrials Summit on Wednesday, August 12, 2026. Conference participation will be in-person and include a Q&A session to discuss dynamics across the various markets PHINIA serves around the world and the Company’s business. PHINIA’s President and CEO, Brady Ericson, and Senior VP and ​CFO, Chris Gropp, will participate in the Q&A session moderated by Brian Willer, Managing Director, Investment Bank at Deutsche Bank. The event will be webcast and available on PHI

Fortitude expands its owned power advantage by energizing its first greenfield build at an attractive power cost Energization expands power portfolio to over 60 MWs of contracted power further supporting Fortitude’s venture mining platform The milestone builds on the previously announced business combination with HeartSciences Inc. (NASDAQ:HSCS) Fortitude Mining Holdings, Inc. ("Fortitude" or the "Company"), a vertically-integrated digital asset mining platform anchored in Zcash, today announced the energization of its new facility in Grand Island, Nebraska. With 12 MW of power capacity now delivered, Fortitude has completed construction, brought the facility online, and validated its

SYDNEY, July 28, 2026 (GLOBE NEWSWIRE) -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, announced the filing of a provisional patent application supporting a novel therapeutic strategy designed to prevent metastatic recurrence in patients with high-risk early-stage triple-negative breast cancer (TNBC). The patent filing is supported by new preclinical findings from a model designed to replicate high-risk early-stage TNBC. In the model, standard treatment —neoadjuvant chemotherapy, anti-PD-1 immunotherapy and surgical resection — followed

Shelton, CT, July 28, 2026 (GLOBE NEWSWIRE) -- HUBBELL REPORTS SECOND QUARTER 2026 RESULTS  Q2 diluted EPS of $4.52; adjusted diluted EPS of $5.52 (up 12% y/y)Q2 net sales +15% (organic +10%; M&A +5%)Q2 operating margin 20.4%; adjusted operating margin 23.9% (down 50 bps y/y)FY 2026 diluted EPS expected range of $17.25-$17.55; raising adj. diluted EPS to $20.25-$20.55 SHELTON, CT. (July 28, 2026) – Hubbell Incorporated (NYSE:HUBB) today reported operating results for the second quarter ended June 30, 2026. "Hubbell delivered strong performance in the second quarter, with double digit growth in sales, adjusted operating profit and adjusted earnings per share" said Gerben Bakker, Chairm

TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O'Grady as its Chief Executive Officer. Mr. O'Grady will lead the Company's next phase of growth, with an initial focus on unlocking the commercial potential of NS002, advancing the Company's pipeline and business development initiatives, and maximizing the value of its proprietary Nasax® intranasal technology platform. Mr. O'Grady succeeds Dan Teleman, with the leadership transition effective Jul

HOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing targeted therapeutics and diagnostics for central nervous system ("CNS") cancers, today announced two posters highlighting its ReSPECT-LM clinical development program and CNSide® cerebrospinal fluid ("CSF") diagnostic platform will be presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology ("SNO/ASCO") CNS Metastases Conference, being held August 13–15, 2026, in Boston, Massachusetts. The Company and its wholly owned subsidiary, CNSide Diagnostics, LLC, will also host a sponsored symposium titled "Redefining th

HOLLISTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August 11, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wil

CASTLE ROCK, Colo., July 28, 2026 (GLOBE NEWSWIRE) -- Riot Platforms, Inc. (NASDAQ:RIOT) ("Riot" or "the Company"), a leader in vertically integrated digital infrastructure specializing in the development of large-scale data centers and bitcoin mining applications, announced today that it has scheduled its second quarter 2026 earnings conference call for Wednesday, August 5, 2026, at 8:30 A.M. EST. This conference call will be available through an audio-only webcast. Please use this link here to register. Participants who choose to dial into the call in the United States or internationally, please use this link here to register. A replay of the webcast will be available after the call end

VANCOUVER, British Columbia, July 28, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (NASDAQ:ZENA) (FSE: 49Q) (BMV:ZENA) ("ZenaTech"), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces that its ZenaDrone subsidiary has commenced the initial flight testing phase of its Interceptor P-1, the Company’s low-cost, one-way autonomous counter-drone platform designed to physically intercept hostile unmanned aerial systems (UAS). The commencement of testing represents a significant step in expanding the Company’s Counter-UAS drone portfolio and integrated defense system. The Interc

Collaboration with Defense Health Agency (DHA) enables Walter Reed 3D Medical Application Center (3D MAC) to achieve first FDA-cleared medical deviceFirst-ever FDA clearance for an implant granted to a point-of-care institutionReinforces 3D Systems’ leadership in guiding healthcare partners from concept to regulatory clearance and commercialization of 3D-printed, patient-specific devices ROCK HILL, S.C., July 28, 2026 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced its role in enabling the Defense Health Agency (DHA) and the Walter Reed National Military Medical Center’s 3D Medical Applications Center (3D MAC) to achieve U.S. Food and Drug Administration (FDA) premarket clearan

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in August. Oppenheimer's Biotech in the Berkshires August 4, 2026, Berkshires, MassachusettsTrevi Representative: Jennifer Good, President and CEO Stifel's 2026 Biotech Summer SummitAugust 10-12, 2026, Newport, Rhode IslandFireside C

TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company"), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. ("HIRONIC"), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The "New Doublo 2.0" is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The d

The Beachbody Company, Inc. (NASDAQ:BODI) ("BODi" or the "Company"), the proactive wellness company delivering nutrition, supplements, and proven fitness programs that help people take control of their health inside and out, will release its second quarter 2026 results on Monday, August 10, 2026, after the U.S. stock market closes. The Company will host a conference call at 5:00 p.m. (Eastern Time) that day to discuss the results. The toll-free dial-in for the conference call is (833) 461-5787 (U.S. & Canada), or click here for Global Dial-In Numbers. The conference ID is 309733825. A live webcast of the conference call will also be available on the Company’s investor relations website at

WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that it will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update. To access the live webcast, including presentation slides, ple